Calcium Disorders: Hypocalcemia and Hypercalcemia

Quick Answer

Calcium Disorders are common and clinically significant electrolyte abnormalities in critically ill patients. Ionized calcium (iCa2+) is the physiologically active fraction and must be measured directly in ICU patients - total calcium adjusted for albumin is unreliable in critical illness.

Key Clinical Features:

• Hypocalcemia: Ionized calcium <1.0 mmol/L; presents with neuromuscular excitability (tetany, Chvostek's sign, Trousseau's sign), seizures, laryngospasm, prolonged QT interval
• Hypercalcemia: Ionized calcium >1.35 mmol/L; presents with "bones, stones, groans, moans"
• skeletal pain, nephrolithiasis, abdominal pain, neuropsychiatric disturbance, shortened QT, Osborn waves

Emergency Management - Hypocalcemia:

1. Calcium gluconate 10% 10-20 mL IV over 10-20 minutes (0.9-1.8 mmol Ca2+)
2. OR Calcium chloride 10% 5-10 mL IV via central line (1.4-2.7 mmol Ca2+)
3. Continuous infusion if ongoing requirements: 1-2 mg/kg/hr elemental calcium
4. Correct hypomagnesemia (essential for PTH function)
5. Address underlying cause (citrate toxicity, post-thyroidectomy, vitamin D deficiency)

Emergency Management - Hypercalcemia:

1. Aggressive IV normal saline (200-500 mL/hr initially) - volume expansion first priority
2. Loop diuretics (frusemide 20-40 mg IV) ONLY AFTER volume replete
3. Bisphosphonates (zoledronic acid 4 mg IV over 15 min) - onset 24-72 hours
4. Calcitonin 4 IU/kg SC/IM q12h - rapid onset but tachyphylaxis in 48 hours
5. Denosumab 60-120 mg SC if bisphosphonate-refractory
6. Dialysis for severe/refractory cases (iCa2+ >4 mmol/L, renal failure)

Mortality:

• Ionized hypocalcemia: 1.5-2x increased ICU mortality (PMID: 15166468)
• Severe hypercalcemia (>3.5 mmol/L): 20-30% in-hospital mortality
• Post-thyroidectomy hypocalcemia: Usually transient, <1% mortality with prompt treatment

Must-Know Facts:

• Always measure ionized calcium - total calcium unreliable in ICU (hypoalbuminemia, acid-base disturbance)
• Calcium gluconate safer peripherally; calcium chloride 3x more elemental Ca2+ but requires central line
• Correct magnesium BEFORE calcium - hypomagnesemia causes PTH resistance
• Massive transfusion: Monitor iCa2+ every 30-60 minutes, replace empirically (1g calcium gluconate per 4 units blood)
• Citrate-based CRRT: Common cause of ICU hypocalcemia, monitor iCa2+ and total:ionized ratio

---

CICM Exam Focus

What Examiners Expect

Second Part Written (SAQ):

Common SAQ stems:

• "A 55-year-old female presents to ICU 6 hours post-total thyroidectomy with paraesthesias and perioral numbness. Serum calcium 1.78 mmol/L (2.10-2.55), ionized calcium 0.85 mmol/L (1.10-1.30). Outline your assessment and management."
• "A 65-year-old male with metastatic lung cancer presents with confusion and dehydration. Corrected calcium 3.8 mmol/L. Discuss the pathophysiology of hypercalcemia of malignancy and outline your ICU management."
• "Describe calcium homeostasis including the roles of PTH, vitamin D, and calcitonin. Explain why ionized calcium is preferred over total calcium in critically ill patients."
• "Outline the causes, clinical features, and management of hypocalcemia during massive transfusion."

Expected depth:

• Detailed calcium physiology (bone-kidney-intestine axis, PTH/vitamin D/calcitonin)
• Understanding of ionized vs total calcium and why albumin correction is unreliable
• Calcium sensing receptor physiology
• Systematic approach to hypocalcemia and hypercalcemia causes
• ECG interpretation (QT prolongation, Osborn waves)
• Evidence-based management including drug dosing, timing, and monitoring
• Special ICU contexts: massive transfusion, citrate-CRRT, post-thyroidectomy

Second Part Hot Case:

Typical presentations:

• Post-thyroidectomy Day 1 with tetany and stridor
• Massive transfusion patient with coagulopathy and haemodynamic instability
• Oncology patient with drowsiness and polyuria
• CRRT patient with citrate toxicity

Examiners assess:

• Recognition of calcium disorder from clinical features and ECG
• Systematic approach to aetiology (not just treatment)
• Understanding of urgency - when is this life-threatening?
• Appropriate monitoring frequency
• Integration with other electrolyte abnormalities (Mg2+, PO43-)
• Communication with surgical/oncology teams

Second Part Viva:

Expected discussion areas:

• Calcium homeostasis: PTH, vitamin D, calcitonin, calcium-sensing receptor
• Ionized vs total calcium: When and why to use each
• ECG changes in calcium disorders with interpretation
• Massive transfusion protocol: Calcium replacement strategies
• Citrate anticoagulation and CRRT: Calcium monitoring, citrate toxicity
• Post-thyroidectomy management: Monitoring, prophylaxis, treatment
• Hypercalcemia of malignancy: PTHrP vs osteolytic mechanisms
• Bisphosphonates vs calcitonin vs denosumab: Mechanism, timing, indications

Examiner expectations:

• Safe, consultant-level decision-making
• Evidence-based practice with guideline awareness
• Understanding that calcium disorders rarely occur in isolation (check Mg2+, PO43-, acid-base)
• Recognition of when dialysis is indicated
• Cultural sensitivity when discussing malignancy-related hypercalcemia prognosis

Common Mistakes

• Using total calcium instead of ionized calcium in ICU patients
• Applying albumin correction formula in critically ill patients (inaccurate due to acid-base disturbance)
• Giving calcium chloride via peripheral line (tissue necrosis)
• Forgetting to check and correct magnesium in refractory hypocalcemia
• Giving frusemide before adequate volume resuscitation in hypercalcemia
• Expecting bisphosphonates to work immediately (24-72 hour onset)
• Not recognising citrate toxicity in CRRT (elevated total:ionized calcium ratio)
• Forgetting hungry bone syndrome post-parathyroidectomy
• Missing hypocalcemia as cause of haemodynamic instability in massive transfusion

---

Key Points

Must-Know Facts

1. Ionized Calcium: The physiologically active fraction (~50% of total); must be measured directly in ICU - total calcium adjusted for albumin is unreliable in critical illness (PMID: 11445649).

2. Calcium Distribution: Total calcium = 50% ionized (active) + 40% albumin-bound + 10% complexed (citrate, phosphate, lactate). Acidosis increases ionized fraction; alkalosis decreases it.

3. Calcium Homeostasis Triad: PTH (↑Ca2+), Vitamin D (↑Ca2+), Calcitonin (↓Ca2+) regulate calcium via bone, kidney, and intestine. Calcium-sensing receptor (CaSR) on parathyroid glands detects and responds to iCa2+ changes within minutes.

4. Normal Ionized Calcium: 1.10-1.30 mmol/L. Critical thresholds: <0.8 mmol/L (severe hypocalcemia), >1.6 mmol/L (severe hypercalcemia).

5. Calcium Gluconate vs Chloride:

   • Gluconate (10 mL of 10% = 0.9 mmol elemental Ca2+): Safe peripherally, slower onset
   • Chloride (10 mL of 10% = 2.7 mmol elemental Ca2+): 3x more elemental Ca2+, requires central line, caustic

6. Magnesium Correction Essential: Hypomagnesemia impairs PTH secretion AND causes PTH resistance - always correct Mg2+ before or with Ca2+ replacement (PMID: 8621774).

7. Massive Transfusion: Citrate in blood products chelates calcium; give 1g calcium gluconate empirically per 4 units blood, or titrate to iCa2+ >1.0 mmol/L. Monitor iCa2+ every 30-60 minutes.

8. Citrate-CRRT Monitoring: Total:ionized calcium ratio >2.5 suggests citrate accumulation; reduce citrate infusion or switch anticoagulation mode (PMID: 19114892).

9. Post-Thyroidectomy Hypocalcemia: Occurs in 20-30% (transient) and 1-2% (permanent). Monitor iCa2+ q6-12h for first 48 hours; prophylactic calcium + calcitriol may reduce severity.

10. Hypercalcemia of Malignancy: 90% due to humoral factors (PTHrP - solid tumours) or local osteolytic factors (bone metastases, myeloma). Prognosis poor; median survival 30-90 days without cancer treatment.

Memory Aids

Mnemonic "CITRATE" for Hypocalcemia Causes:

• C: Citrate (massive transfusion, CRRT)
• I: Inadequate PTH (hypoparathyroidism, post-thyroidectomy)
• T: Total body deficiency (vitamin D deficiency, malabsorption)
• R: Rhabdomyolysis (calcium sequestration in muscle)
• A: Acute pancreatitis (saponification)
• T: Transfusion (citrate anticoagulant)
• E: Electrolyte related (hyperphosphataemia, hypomagnesaemia)

"Bones, Stones, Groans, Moans" for Hypercalcemia:

• Bones: Bone pain, fractures, osteitis fibrosa cystica
• Stones: Nephrolithiasis, nephrocalcinosis
• Groans: Abdominal pain, constipation, pancreatitis, peptic ulcers
• Moans: Psychiatric symptoms (depression, confusion, psychosis)

ECG Changes Memory Aid:

• Hypocalcemia = "Long QT" = Prolonged QTc (risk of Torsades)
• Hypercalcemia = "Short QT" = Shortened QTc + J waves (Osborn waves)

---

Definition & Epidemiology

Definitions

Hypocalcemia is defined as:

• Ionized calcium (iCa2+) <1.10 mmol/L (preferred ICU definition)
• OR Total calcium <2.10 mmol/L (adjusted for albumin - less reliable)
• Severity: Mild (iCa2+ 0.9-1.1), Moderate (iCa2+ 0.8-0.9), Severe (<0.8 mmol/L)

Hypercalcemia is defined as:

• Ionized calcium (iCa2+) >1.35 mmol/L (preferred ICU definition)
• OR Total calcium >2.60 mmol/L (adjusted for albumin)
• Severity: Mild (2.6-3.0 mmol/L), Moderate (3.0-3.5 mmol/L), Severe/Crisis (>3.5 mmol/L)

Albumin Correction Formulas (use with caution in ICU - unreliable):

• Corrected Ca2+ = Total Ca2+ + 0.02 × (40 - Albumin g/L)
• OR Corrected Ca2+ = Total Ca2+ + 0.8 × (4 - Albumin g/dL)

Why Ionized Calcium is Essential in ICU (PMID: 11445649):

1. Hypoalbuminemia is ubiquitous in critical illness
2. Acid-base disturbances alter protein binding (acidosis ↓binding, alkalosis ↑binding)
3. Heparin, citrate, and lactate alter complexed fraction
4. Total calcium with albumin correction has <50% concordance with ionized calcium in ICU patients

Epidemiology

Hypocalcemia in ICU (PMID: 15166468, 23773506):

• Incidence: 15-88% of ICU patients depending on definition and population
• Ionized hypocalcemia (<1.0 mmol/L): 12-20% of ICU admissions
• Severe hypocalcemia (<0.8 mmol/L): 2-5% of ICU patients
• Trauma ICU: Up to 50% in first 24 hours
• Cardiac surgery: 70-90% intraoperatively (haemodilution, citrate)
• Sepsis: 70% at some point during ICU stay

Hypercalcemia in ICU (PMID: 16625125):

• Incidence: 2-5% of ICU admissions
• Most common cause in ICU: Malignancy (50-60%)
• Primary hyperparathyroidism: 10-20%
• Severe hypercalcemia (>3.5 mmol/L): 0.5-1% of ICU patients

Australian/NZ Context:

• Massive transfusion protocols: Standard in all major trauma centres
• Citrate-based CRRT: Increasingly common (now standard in many Australian ICUs)
• Post-thyroidectomy hypocalcemia: 1,500-2,000 thyroidectomies annually in Australia
• Malignancy-associated hypercalcemia: Common given aging population

Indigenous Health Considerations (PMID: 25187269):

• Aboriginal and Torres Strait Islander peoples: Higher rates of vitamin D deficiency (30-50% prevalence)
• Darker skin pigmentation reduces vitamin D synthesis
• Geographic remoteness limits dietary diversity and sun exposure at higher latitudes
• Higher rates of chronic kidney disease affecting vitamin D activation
• Limited access to specialist endocrine services
• Māori populations (NZ): Similar vitamin D deficiency patterns, higher CKD rates
• Cultural considerations: Dietary restrictions, traditional healing integration

Mortality Impact (PMID: 15166468):

• Ionized hypocalcemia independently associated with 1.5-2x increased ICU mortality
• OR 1.7 (95% CI 1.3-2.2) for iCa2+ <1.0 mmol/L
• Severe hypercalcemia (>3.5 mmol/L): 20-30% in-hospital mortality
• Hypercalcemia of malignancy: Median survival 30-90 days without cancer treatment

---

Applied Basic Sciences

This section bridges First Part basic sciences with Second Part clinical practice

Anatomy

Parathyroid Glands:

• Four glands (superior and inferior pairs) located posterior to thyroid gland
• Superior: Derived from 4th pharyngeal pouch, more constant position
• Inferior: Derived from 3rd pharyngeal pouch, variable position (may be in thymus)
• Blood supply: Inferior thyroid artery (primarily)
• Each gland weighs 30-50 mg; total parathyroid tissue ~120-200 mg
• Chief cells: Produce PTH
• Oxyphil cells: Function unclear, increase with age

Thyroid C Cells (Parafollicular Cells):

• Derived from neural crest (ultimobranchial body)
• Located between thyroid follicles
• Produce calcitonin
• Site of origin for medullary thyroid carcinoma

Relevant Renal Anatomy:

• Proximal tubule: 60-70% calcium reabsorption (passive, paracellular)
• Thick ascending limb of Henle: 20-25% reabsorption (paracellular, driven by positive lumen potential)
• Distal convoluted tubule: 8-10% reabsorption (active, transcellular, PTH-regulated)
• Collecting duct: Minimal reabsorption

Bone Architecture:

• Cortical bone: 80% of skeleton, slow turnover
• Trabecular bone: 20% of skeleton, rapid turnover, metabolically active
• Osteoblasts: Bone formation, express RANKL
• Osteoclasts: Bone resorption, activated by RANKL
• Osteocytes: Mechanosensing, regulate phosphate (FGF-23)

Physiology

Calcium Homeostasis: The Bone-Kidney-Intestine Axis

Total body calcium: ~1000g (99% in bone as hydroxyapatite, 1% intracellular, 0.1% extracellular)

Daily calcium flux:

• Dietary intake: 800-1200 mg/day
• Intestinal absorption: 200-400 mg/day (net, vitamin D dependent)
• Renal filtration: 10,000 mg/day (180L × 2.5 mmol/L × 50% ionized)
• Renal reabsorption: 9,800-9,900 mg/day (98-99%)
• Urinary excretion: 100-200 mg/day
• Bone turnover: 500 mg/day enters and leaves bone

Parathyroid Hormone (PTH) (PMID: 30629691):

Structure: 84 amino acid polypeptide (PTH 1-84); N-terminal fragment (1-34) is bioactive

Regulation:

• Calcium-sensing receptor (CaSR) on parathyroid chief cells
• ↓iCa2+ → ↓CaSR activation → ↑PTH secretion (within seconds)
• ↑iCa2+ → ↑CaSR activation → ↓PTH secretion
• Magnesium: Severe hypomagnesemia inhibits PTH secretion
• Vitamin D: 1,25(OH)2D suppresses PTH gene transcription

Actions of PTH:

1. Bone (within hours):

   • Stimulates osteoclasts (indirect via osteoblast RANKL expression)
   • Releases calcium and phosphate from bone

2. Kidney (within minutes):

   • ↑Calcium reabsorption in distal tubule (TRPV5 channels)
   • ↓Phosphate reabsorption in proximal tubule (NaPi-IIa/IIc downregulation)
   • ↑1α-hydroxylase activity → ↑1,25(OH)2D synthesis

3. Intestine (indirect, via vitamin D, within days):

   • ↑Calcium absorption
   • ↑Phosphate absorption

Net effect: ↑Serum calcium, ↓Serum phosphate

Vitamin D Metabolism (PMID: 31331097):

Pathway:

1. Skin: 7-dehydrocholesterol → Vitamin D3 (cholecalciferol) via UVB
2. Liver: Vitamin D3 → 25(OH)D (calcidiol) via 25-hydroxylase (CYP2R1)
3. Kidney: 25(OH)D → 1,25(OH)2D (calcitriol, active form) via 1α-hydroxylase (CYP27B1)

Regulation of 1α-hydroxylase:

• Stimulated by: PTH, hypophosphataemia, hypocalcaemia
• Inhibited by: 1,25(OH)2D (negative feedback), FGF-23, hyperphosphataemia

Actions of 1,25(OH)2D:

1. Intestine (primary site):

   • ↑Calcium absorption via TRPV6 channels and calbindin
   • ↑Phosphate absorption via NaPi-IIb

2. Bone:

   • Permits mineralisation (maintains Ca × PO4 product)
   • With PTH, stimulates osteoclast-mediated resorption

3. Parathyroid gland:

   • Suppresses PTH gene transcription (negative feedback)

4. Kidney:

   • ↑Calcium and phosphate reabsorption

Calcitonin (PMID: 20472767):

Structure: 32 amino acid peptide from thyroid C cells

Regulation:

• Released in response to ↑serum calcium
• Also stimulated by gastrin, CCK (explains postprandial release)

Actions:

• Inhibits osteoclast activity → ↓bone resorption
• ↓Renal calcium reabsorption
• Minor physiological role in humans (thyroidectomy patients have normal calcium)
• Pharmacological doses: Rapid calcium-lowering effect

Clinical relevance:

• Used therapeutically in hypercalcemia (rapid but transient effect)
• Tumour marker for medullary thyroid carcinoma
• Tachyphylaxis limits long-term use (receptor downregulation)

Calcium-Sensing Receptor (CaSR) (PMID: 25612513):

Location: Parathyroid glands (primary), kidney (thick ascending limb, collecting duct), bone, brain

Function:

• G-protein coupled receptor (GPCR) that senses extracellular iCa2+
• Sets the "set point" for calcium homeostasis
• Parathyroid: ↑iCa2+ → ↑CaSR → ↓PTH secretion
• Kidney: ↑iCa2+ → ↑CaSR → ↓calcium reabsorption (calciuria)

Clinical relevance:

• Familial hypocalciuric hypercalcemia (FHH): Inactivating CaSR mutation → elevated set point
• Autosomal dominant hypocalcemia: Activating CaSR mutation → low set point
• Calcimimetics (cinacalcet): Allosteric CaSR activators used in hyperparathyroidism

Ionized vs Total Calcium

Distribution of plasma calcium:

• Ionized (free): ~50% (1.10-1.30 mmol/L) - PHYSIOLOGICALLY ACTIVE
• Protein-bound: ~40% (primarily albumin)
• Complexed: ~10% (citrate, phosphate, lactate, bicarbonate)

Factors affecting ionized calcium fraction:

Why Albumin Correction Fails in ICU (PMID: 11445649):

The formula: Corrected Ca = Measured Ca + 0.02 × (40 - Albumin)

Limitations in critical illness:

1. Assumes normal pH (incorrect in most ICU patients)
2. Assumes normal protein binding (altered by drugs, acid-base)
3. Does not account for complexed calcium changes
4. <50% concordance with measured ionized calcium

ALWAYS measure ionized calcium directly in ICU patients

Pathophysiology

Hypocalcemia Mechanisms

1. Decreased PTH (Hypoparathyroidism):

• Post-surgical: Most common cause; 20-30% transient, 1-2% permanent after thyroidectomy
• Autoimmune: Part of autoimmune polyglandular syndrome
• Infiltrative: Haemochromatosis, Wilson's disease, metastases
• Genetic: DiGeorge syndrome (22q11 deletion), AIRE mutations
• Irradiation: Neck radiotherapy

2. PTH Resistance (Pseudohypoparathyroidism):

• Target organ resistance to PTH (GNAS1 mutations)
• PTH elevated but ineffective
• Albright hereditary osteodystrophy phenotype

3. Vitamin D Deficiency/Resistance:

• Nutritional deficiency (endemic in Australia, especially Indigenous populations)
• Malabsorption (coeliac disease, gastric bypass, short bowel)
• Chronic kidney disease (↓1α-hydroxylase activity)
• Liver disease (↓25-hydroxylation)
• Vitamin D-dependent rickets (1α-hydroxylase or VDR mutations)

4. Calcium Sequestration:

• Acute pancreatitis: Fat saponification binds calcium; severity correlates with hypocalcemia
• Rhabdomyolysis: Calcium influx into damaged muscle; may develop hypercalcemia in recovery phase
• Citrate toxicity: Massive transfusion, plasmapheresis, citrate-based CRRT
• Tumour lysis syndrome: Hyperphosphataemia → calcium-phosphate precipitation
• Hungry bone syndrome: Post-parathyroidectomy influx of calcium into calcium-depleted bone

5. Chelation and Binding:

• Citrate (blood products, CRRT anticoagulation)
• EDTA (some medications, laboratory contamination)
• Foscarnet (antiviral)
• Phosphate (iatrogenic, tumour lysis, rhabdomyolysis)

6. Hypomagnesemia (PMID: 8621774):

• Impairs PTH secretion (magnesium required for PTH release)
• Causes PTH resistance at target organs
• Must correct Mg2+ for calcium replacement to be effective
• Common in alcoholism, diuretic use, CRRT

Massive Transfusion and Citrate Toxicity (PMID: 25647203):

Citrate in blood products:

• Each unit of PRBCs contains ~3g citrate
• Citrate chelates ionized calcium
• Normal hepatic metabolism clears ~3g citrate per 5 minutes
• Rapid transfusion (>1 unit per 5 minutes) overwhelms metabolism

Risk factors for citrate toxicity:

• Rapid transfusion rate
• Hypothermia (↓hepatic metabolism)
• Hepatic dysfunction
• Hypoperfusion/shock states

The "Lethal Diamond" extends the classic lethal triad:

• Hypothermia
• Acidosis
• Coagulopathy
• Hypocalcemia (fourth factor)

Citrate-Based CRRT and Calcium (PMID: 19114892):

Regional citrate anticoagulation:

• Citrate infused pre-filter to chelate calcium
• Prevents circuit clotting
• Calcium infused post-filter to replace chelated calcium
• Monitor ionized calcium (both systemic and circuit)

Citrate accumulation:

• Occurs with liver dysfunction, shock, impaired tissue perfusion
• Total:ionized calcium ratio >2.5 suggests accumulation
• Metabolic alkalosis (citrate metabolised to bicarbonate)
• Widening anion gap
• Treatment: Reduce citrate dose, switch to heparin anticoagulation

Hypercalcemia Mechanisms

1. Humoral Hypercalcemia of Malignancy (HHM) (PMID: 16625125):

• PTH-related peptide (PTHrP) secretion by tumours
• Squamous cell carcinomas (lung, head/neck, oesophagus), renal cell, breast, bladder
• PTHrP binds PTH/PTHrP receptor with similar affinity to PTH
• Effects: ↑Bone resorption, ↑renal calcium reabsorption, ↓phosphate reabsorption
• Accounts for 80% of hypercalcemia of malignancy

2. Local Osteolytic Hypercalcemia (LOH):

• Direct bone destruction by metastases
• Breast cancer, multiple myeloma, lymphoma
• Tumour cells secrete cytokines (IL-1, IL-6, TNF-α) that activate osteoclasts
• Accounts for ~20% of hypercalcemia of malignancy

3. Primary Hyperparathyroidism:

• Parathyroid adenoma (85%), hyperplasia (10-15%), carcinoma (<1%)
• Inappropriate PTH secretion despite elevated calcium
• Most common cause of outpatient hypercalcemia; less common in ICU

4. Vitamin D Toxicity:

• Exogenous vitamin D overdose
• Granulomatous disease (sarcoidosis, TB): Macrophage 1α-hydroxylase activity
• Lymphoma: Tumour 1α-hydroxylase activity

5. Other Causes:

• Immobilisation (↑bone resorption without proportional formation)
• Thiazide diuretics (↓renal calcium excretion)
• Milk-alkali syndrome (calcium + alkali intake)
• Pheochromocytoma (ectopic PTHrP)
• Adrenal insufficiency (volume contraction)
• Thyrotoxicosis (increased bone turnover)

Pharmacology

Calcium Preparations

1. Calcium Gluconate 10% (PMID: 16625125)

• Elemental calcium: 0.9 mmol (36 mg) per 10 mL ampoule
• Administration: IV push over 2-3 minutes OR infusion
• Peripheral line: SAFE (pH ~6.5, less irritant)
• Dilution: Dilute in D5W or NS (not compatible with bicarbonate)
• Onset: 5-10 minutes
• Duration: 2-4 hours
• Monitoring: Continuous ECG during bolus

Dosing for acute hypocalcemia:

• Bolus: 10-20 mL (1-2 ampoules) over 10-20 minutes
• May repeat q10-20 minutes for severe symptoms
• Infusion: 10 ampoules (100 mL) in 1L NS at 50-100 mL/hr (adjust to iCa2+)

2. Calcium Chloride 10% (PMID: 16625125)

• Elemental calcium: 2.7 mmol (108 mg) per 10 mL ampoule
• Administration: IV push over 2-3 minutes OR infusion
• Central line REQUIRED: Highly caustic (pH ~6.5 but hyperosmolar)
• Peripheral extravasation: Severe tissue necrosis
• Onset: Immediate (more rapid than gluconate)
• Duration: 2-4 hours
• Advantage: 3× more elemental calcium per mL than gluconate

Dosing for cardiac arrest/severe hypocalcemia:

• Bolus: 10 mL (1 ampoule) over 2-3 minutes via central line
• May repeat in 10 minutes if no response
• Preferred in cardiac arrest (more rapid calcium delivery)

Comparison:

3. Oral Calcium Supplements

• Calcium carbonate: 40% elemental calcium, requires gastric acid
• Calcium citrate: 21% elemental calcium, acid-independent
• Dosing: 1-3 g elemental calcium daily in divided doses
• Use: Maintenance therapy, post-thyroidectomy

Vitamin D Preparations

1. Calcitriol (1,25-dihydroxyvitamin D3)

• Active form; no hepatic or renal activation required
• Dose: 0.25-1 mcg twice daily
• Onset: Rapid (1-2 days)
• Duration: Short half-life (4-6 hours)
• Use: Hypoparathyroidism, CKD

2. Cholecalciferol (Vitamin D3)

• Requires hepatic 25-hydroxylation and renal 1α-hydroxylation
• Dose: 1000-5000 IU daily; loading 50,000 IU weekly
• Onset: Slow (weeks)
• Duration: Long (weeks)
• Use: Vitamin D deficiency

Hypercalcemia Treatments

1. Normal Saline (PMID: 16625125)

• Mechanism: Volume expansion, ↑GFR, ↑calcium excretion
• Rate: 200-500 mL/hr initially (monitor volume status)
• Target: Urine output 200-300 mL/hr
• Caution: Heart failure, renal impairment
• First-line treatment - correct dehydration BEFORE diuretics

2. Loop Diuretics (Frusemide)

• Mechanism: Inhibits NKCC2 in thick ascending limb, ↓paracellular calcium reabsorption
• Dose: 20-40 mg IV after volume replete
• ONLY use after adequate hydration - dehydration worsens hypercalcemia
• Limited role; may exacerbate volume depletion

3. Bisphosphonates (PMID: 18558708)

Zoledronic Acid (Zometa):

• Mechanism: Binds hydroxyapatite, inhibits osteoclast function, induces osteoclast apoptosis
• Dose: 4 mg IV over 15 minutes
• Onset: 24-72 hours (NOT for acute emergency)
• Duration: 2-4 weeks
• Renal dosing: Reduce dose if CrCl <60 mL/min; avoid if <30 mL/min
• Adverse effects: Acute phase reaction (flu-like), renal toxicity, osteonecrosis of jaw (rare)
• PBS: Listed for hypercalcemia of malignancy

Pamidronate:

• Dose: 60-90 mg IV over 2-4 hours
• Onset: 24-72 hours
• Less potent than zoledronic acid but longer safety record

4. Calcitonin (PMID: 20472767)

• Mechanism: Inhibits osteoclast activity, ↑renal calcium excretion
• Dose: 4-8 IU/kg SC or IM q6-12h
• Onset: 4-6 hours (fastest onset of bone-active agents)
• Duration: 48-72 hours (tachyphylaxis develops)
• Use: Bridge therapy while awaiting bisphosphonate effect
• Adverse effects: Nausea, flushing, tachyphylaxis

5. Denosumab (PMID: 24625731)

• Mechanism: RANKL inhibitor; prevents osteoclast maturation and activity
• Dose: 60-120 mg SC
• Onset: 2-4 days
• Duration: 4-8 weeks
• Use: Bisphosphonate-refractory hypercalcemia, renal impairment (not renally cleared)
• Advantage: Safe in renal failure (unlike bisphosphonates)
• Risk: Severe rebound hypercalcemia when discontinued

6. Glucocorticoids (PMID: 16625125)

• Mechanism: ↓Intestinal calcium absorption, ↓1α-hydroxylase in granulomatous tissue
• Dose: Hydrocortisone 200-300 mg/day or prednisone 40-60 mg/day
• Onset: 2-5 days
• Use: Vitamin D toxicity, granulomatous disease (sarcoidosis, TB), haematological malignancy
• NOT effective for PTH-mediated or PTHrP-mediated hypercalcemia

7. Dialysis

• Mechanism: Direct calcium removal
• Indication: Severe hypercalcemia (>4.5 mmol/L), renal failure, refractory to medical therapy
• Use low-calcium or calcium-free dialysate
• CRRT effective for sustained calcium control

---

Clinical Presentation

Hypocalcemia

Neuromuscular Manifestations (most characteristic):

Mild (iCa2+ 0.9-1.0 mmol/L):

• Perioral numbness and paraesthesias
• Tingling in fingers and toes
• Muscle cramps
• Irritability

Moderate (iCa2+ 0.8-0.9 mmol/L):

• Carpopedal spasm
• Muscle twitching
• Chvostek's sign positive (may be present in 10% of normal individuals)
• Trousseau's sign positive (more specific)
• Hyperreflexia

Severe (iCa2+ <0.8 mmol/L):

• Tetany (tonic muscle spasms)
• Laryngospasm and stridor (life-threatening)
• Bronchospasm
• Generalised seizures
• Altered mental status

Clinical Signs:

Chvostek's Sign:

• Tapping facial nerve anterior to ear
• Positive: Ipsilateral facial muscle twitching
• Sensitivity: 10-30% (low)
• Specificity: 70% (moderate)
• Present in 10% of normocalcemic individuals

Trousseau's Sign:

• Inflate BP cuff above systolic for 3 minutes
• Positive: Carpal spasm (flexion at wrist and MCP, extension at IP joints - "obstetric hand")
• Sensitivity: 94%
• Specificity: 99%
• More reliable than Chvostek's sign

Cardiovascular Manifestations:

ECG Changes (PMID: 17884576):

• Prolonged QT interval (predominantly ST segment prolongation)
• QTc >500 ms: High risk of Torsades de Pointes
• T wave flattening or inversion
• Bradycardia
• Heart block (severe cases)
• Refractory hypotension (impaired myocardial contractility)
• Decreased response to inotropes and vasopressors

Haemodynamic Effects:

• Decreased myocardial contractility
• Hypotension resistant to vasopressors
• Impaired response to catecholamines
• Heart failure exacerbation

Other Manifestations:

• Psychiatric: Anxiety, depression, psychosis, delirium
• Dermatological: Dry skin, brittle nails, coarse hair
• Dental: Enamel hypoplasia, dental caries
• Ophthalmological: Cataracts (chronic hypocalcemia)
• GI: Abdominal cramps, dysphagia

Hypercalcemia

Classic Triad: "Bones, Stones, Groans, Moans + Thrones"

Bones (Skeletal):

• Bone pain
• Pathological fractures
• Osteitis fibrosa cystica (brown tumours in hyperparathyroidism)
• Subperiosteal bone resorption

Stones (Renal):

• Nephrolithiasis (calcium oxalate/phosphate stones)
• Nephrocalcinosis
• Nephrogenic diabetes insipidus (concentrating defect)
• Polyuria and polydipsia
• Acute kidney injury (from dehydration, nephrocalcinosis)

Groans (Gastrointestinal):

• Anorexia, nausea, vomiting
• Constipation
• Abdominal pain
• Acute pancreatitis
• Peptic ulcer disease

Moans (Neuropsychiatric):

• Lethargy, fatigue
• Depression
• Confusion, delirium
• Psychosis
• Coma (severe hypercalcemia)
• Muscle weakness

Thrones (Urinary):

• Polyuria (nephrogenic DI)
• Nocturia
• Dehydration

Cardiovascular Manifestations:

ECG Changes (PMID: 17884576):

• Shortened QT interval (shortened ST segment)
• QTc <350 ms characteristic
• Osborn (J) waves may be present
• PR prolongation (first-degree heart block)
• Wide QRS (severe)
• Bradycardia
• Digitalises toxicity potentiation (hypercalcemia + digoxin dangerous)

Arrhythmias:

• Bradyarrhythmias
• Complete heart block
• Ventricular arrhythmias (rare)
• Cardiac arrest (severe hypercalcemia)

Severity Classification:

---

Investigations

Laboratory Tests

First-Line (All Patients):

Second-Line (Based on Clinical Context):

ICU-Specific Monitoring:

Massive Transfusion:

• iCa2+ every 30-60 minutes during active transfusion
• Target iCa2+ >1.0 mmol/L (some protocols >1.1 mmol/L)
• Consider empiric replacement: 1g calcium gluconate per 4 units blood

Citrate-Based CRRT (PMID: 19114892):

• Systemic iCa2+ q4-6h initially, then q12h when stable
• Post-filter iCa2+ (circuit calcium) to titrate citrate
• Total:ionized calcium ratio (if >2.5, suggests citrate accumulation)
• Monitor for metabolic alkalosis (citrate → bicarbonate)

Post-Thyroidectomy:

• iCa2+ 6 hours post-op, then q6-12h for 48-72 hours
• PTH at 4-6 hours post-op (if <15 pg/mL, high risk of hypocalcemia)
• Watch for symptoms even with borderline calcium

Electrocardiogram

Hypocalcemia ECG Features:

• QT prolongation: Predominantly ST segment prolongation (not T wave)
• Calculate QTc using Bazett's formula: QTc = QT / √RR
• QTc >500 ms: Significant risk of Torsades de Pointes
• T wave flattening or inversion
• U waves (sometimes)
• Bradycardia
• AV block (severe cases)

Hypercalcemia ECG Features:

• QT shortening: Predominantly short ST segment
• QTc <350 ms characteristic
• Osborn (J) waves may be present (especially if concurrent hypothermia)
• PR prolongation
• Widened QRS (severe)
• Bradycardia
• AV block
• Note: Digoxin toxicity potentiated by hypercalcemia

ECG Interpretation Pearls:

• Always measure QT in multiple leads (use lead with clearest T wave end)
• Correct for heart rate (QTc)
• Hypocalcemia prolongs ST segment; hypokalaemia prolongs T wave to U wave interval
• Short QT syndrome mimics hypercalcemia ECG

Imaging

Hypocalcemia Workup:

• Neck ultrasound: If post-thyroidectomy (haematoma, residual parathyroid tissue)
• Renal ultrasound: If CKD suspected
• DEXA scan: Chronic hypoparathyroidism (high bone density paradoxically)

Hypercalcemia Workup:

• CT chest/abdomen/pelvis: Malignancy search
• Parathyroid imaging (sestamibi, 4D-CT): If primary hyperparathyroidism
• Bone scan: Skeletal metastases
• PET-CT: If occult malignancy suspected
• Renal ultrasound: Nephrolithiasis, nephrocalcinosis

---

ICU Management

Hypocalcemia Management

Immediate Assessment:

1. Confirm ionized hypocalcemia (not just low total calcium)
2. Assess severity and symptoms
3. Check magnesium (must correct simultaneously)
4. Identify and treat underlying cause
5. Continuous ECG monitoring if iCa2+ <0.9 mmol/L or symptomatic

Acute Symptomatic Hypocalcemia (tetany, seizures, laryngospasm):

Step 1: Calcium Gluconate IV

• Dose: 10-20 mL of 10% calcium gluconate IV over 10-20 minutes
• Repeat every 10-20 minutes until symptoms controlled
• Maximum: 50 mL (5 ampoules) before reassessing

Step 2: Continuous Infusion

• After bolus, start infusion: 10 ampoules (100 mL) calcium gluconate in 1L NS or D5W
• Rate: 50-100 mL/hr (0.5-2 mg/kg/hr elemental calcium)
• Titrate to iCa2+ >1.0 mmol/L and symptom resolution

Step 3: Correct Magnesium

• If Mg2+ <0.7 mmol/L: MgSO4 2-4 g IV over 20-60 minutes
• Maintenance: 1-2 g MgSO4 q6h or infusion 1-2 g per 24h
• Target Mg2+ >0.8 mmol/L

Step 4: Address Underlying Cause

• Massive transfusion: Continue calcium replacement, warm products
• Citrate CRRT: Reduce citrate, increase calcium replacement
• Post-thyroidectomy: Calcitriol 0.5-1 mcg BD + oral calcium
• Vitamin D deficiency: Cholecalciferol loading + calcitriol

Calcium Chloride (Central Line):

• Reserved for cardiac arrest or severe haemodynamic instability
• Dose: 10 mL of 10% calcium chloride IV over 2-3 minutes
• Provides 3× more elemental calcium than gluconate
• NEVER give peripherally - tissue necrosis

Monitoring During Acute Treatment:

• iCa2+ every 1-2 hours until stable
• Continuous ECG (watch for QT normalisation)
• Phosphate (high phosphate impairs calcium repletion)
• Magnesium (recheck after initial correction)

Transition to Maintenance:

• Oral calcium carbonate 1-3 g daily in divided doses
• Calcitriol 0.25-0.5 mcg twice daily (titrate to maintain iCa2+)
• Cholecalciferol 1000-4000 IU daily (if vitamin D deficient)
• Target iCa2+ 1.0-1.1 mmol/L (lower end to avoid hypercalciuria)

Hypercalcemia Management

Immediate Assessment:

1. Confirm severity (ionized calcium preferred)
2. Assess volume status (usually dehydrated)
3. Identify likely cause (malignancy vs hyperparathyroidism)
4. Evaluate for end-organ dysfunction (AKI, cardiac)
5. Continuous ECG monitoring if calcium >3.5 mmol/L

Severity-Based Management:

Mild Hypercalcemia (2.6-3.0 mmol/L, asymptomatic):

• Oral hydration
• Mobilise (reduce bone resorption)
• Discontinue calcium-elevating drugs (thiazides, lithium, vitamin D)
• Address underlying cause

Moderate Hypercalcemia (3.0-3.5 mmol/L):

Step 1: Volume Expansion (FIRST PRIORITY) (PMID: 16625125)

• Normal saline 200-500 mL/hr initially
• Target urine output 200-300 mL/hr
• Typical deficit: 3-6 litres
• Monitor for volume overload (especially in elderly, cardiac disease)

Step 2: Loop Diuretics (ONLY after volume replete)

• Frusemide 20-40 mg IV if evidence of volume overload
• NOT routine first-line therapy
• Premature diuretics worsen volume depletion and hypercalcemia

Step 3: Bisphosphonates (PMID: 18558708)

• Zoledronic acid 4 mg IV over 15 minutes (first-line)
• OR Pamidronate 60-90 mg IV over 2-4 hours
• Onset: 24-72 hours (not for acute emergency)
• Adjust dose for renal function

Step 4: Calcitonin (Bridge therapy)

• Calcitonin 4-8 IU/kg SC or IM q6-12h
• Onset: 4-6 hours
• Provides rapid effect while awaiting bisphosphonate
• Tachyphylaxis develops in 48-72 hours
• Discontinue after bisphosphonate takes effect

Severe Hypercalcemia (>3.5 mmol/L) or Crisis:

All of the above PLUS:

Denosumab (if bisphosphonate-refractory or contraindicated) (PMID: 24625731):

• Dose: 60-120 mg SC
• Advantage: Safe in renal failure
• Onset: 2-4 days
• Caution: Severe rebound hypercalcemia when stopped

Glucocorticoids (if vitamin D-mediated or haematological malignancy):

• Hydrocortisone 200-300 mg/day IV
• OR Prednisone 40-60 mg/day oral
• Effective for granulomatous disease, vitamin D toxicity, lymphoma/myeloma

Dialysis (if refractory or AKI):

• Severe hypercalcemia (>4.5 mmol/L) with renal failure
• Refractory to medical therapy
• Life-threatening arrhythmias
• Use low-calcium or calcium-free dialysate
• CRRT effective for sustained control

Parathyroidectomy (if primary hyperparathyroidism):

• Urgent surgery if severe symptomatic hypercalcemia
• Prepare for hungry bone syndrome post-operatively

Monitoring During Acute Treatment:

• iCa2+ every 4-6 hours initially, then daily
• Renal function (may improve with hydration)
• Electrolytes (hypokalaemia common with diuresis)
• Volume status (clinical + CVP if available)
• ECG (QT normalisation)

ICU-Specific Scenarios

Massive Transfusion Protocol (PMID: 25647203):

Citrate load:

• Each unit PRBCs: ~3g citrate
• Each unit FFP: ~5g citrate
• Normal metabolism: ~3g per 5 minutes

Empiric replacement strategy:

• Give 1g calcium gluconate IV per 4 units blood products
• OR titrate to iCa2+ >1.0 mmol/L (check every 30-60 minutes)
• Use calcium chloride via central line if cardiac arrest or severe instability

Risk factors for citrate toxicity:

• Transfusion rate >1 unit per 5 minutes
• Hypothermia (<35°C)
• Hepatic dysfunction
• Shock states

Goals during massive transfusion:

• iCa2+ >1.0 mmol/L (some protocols target >1.1 mmol/L)
• Temperature >35°C
• pH >7.2
• Fibrinogen >1.5 g/L

Citrate-Based CRRT (PMID: 19114892):

Protocol:

• Citrate infused pre-filter (chelates calcium, prevents clotting)
• Calcium chloride or gluconate infused post-filter (replaces systemic calcium)
• Monitor systemic iCa2+ (target 1.0-1.2 mmol/L)
• Monitor post-filter iCa2+ (target 0.25-0.35 mmol/L for anticoagulation)

Signs of citrate accumulation:

• Elevated total:ionized calcium ratio (>2.5)
• Metabolic alkalosis (citrate metabolised to bicarbonate)
• Widening anion gap
• Rising lactate (citrate interferes with lactate metabolism)

Management of citrate toxicity:

1. Reduce citrate infusion rate
2. Increase dialysate flow (if CVVHDF)
3. Consider switching to heparin anticoagulation
4. Correct hypocalcemia with supplemental calcium

Post-Thyroidectomy Monitoring:

Risk factors for hypocalcemia:

• Total thyroidectomy (vs hemithyroidectomy)
• Concurrent parathyroidectomy
• Lymph node dissection for cancer
• Revision surgery
• Graves' disease (hungry bone syndrome)
• Low preoperative vitamin D

Monitoring protocol:

• iCa2+ at 6 hours post-op, then q6-12h for 48 hours
• PTH at 4-6 hours post-op (if <15 pg/mL, high risk)
• Watch for symptoms even with borderline calcium

Prophylaxis (if high risk):

• Calcium carbonate 1-3 g daily in divided doses
• Calcitriol 0.25-0.5 mcg twice daily
• May reduce severity and duration of hypocalcemia

Treatment of post-thyroidectomy hypocalcemia:

• Mild: Oral calcium + calcitriol, monitor closely
• Moderate/symptomatic: IV calcium gluconate, then transition to oral
• Stridor/laryngospasm: EMERGENCY - secure airway, IV calcium, call surgeon

Hungry Bone Syndrome (Post-parathyroidectomy):

Mechanism:

• After parathyroidectomy for hyperparathyroidism, PTH levels drop rapidly
• Calcium, phosphate, and magnesium rapidly taken up by calcium-depleted bone
• More severe if preoperative bone disease (osteitis fibrosa cystica)

Clinical features:

• Profound hypocalcemia (may be severe)
• Hypophosphataemia
• Hypomagnesaemia
• Onset: 12-72 hours post-surgery

Management:

• High-dose calcium replacement (may require 10-12 g elemental calcium daily)
• Calcitriol 0.5-1 mcg twice daily (high doses)
• Magnesium replacement
• Phosphate replacement if severe
• Duration: Days to weeks (bone remineralisation)

---

Prognosis

Hypocalcemia Prognosis

Based on Aetiology:

ICU Outcomes (PMID: 15166468):

• Ionized hypocalcemia associated with 1.5-2x increased mortality
• OR 1.7 (95% CI 1.3-2.2) for iCa2+ <1.0 mmol/L
• Hypocalcemia is often marker of illness severity rather than direct cause of death
• Early correction may improve haemodynamic stability and inotrope response

Long-term Complications of Chronic Hypocalcemia:

• Cataracts
• Basal ganglia calcifications
• Dental enamel hypoplasia
• Dilated cardiomyopathy
• Renal stones (if overtreated with oral calcium)

Hypercalcemia Prognosis

Based on Aetiology:

Hypercalcemia of Malignancy (PMID: 16625125):

• Typically indicates advanced/metastatic disease
• Median survival 30-90 days without cancer treatment
• Better prognosis if:
  • Cancer responsive to treatment
  • Solid tumour with surgical option
  • Haematological malignancy (often treatment-responsive)
• Poor prognostic factors:
  • Higher calcium level
  • Shorter interval from cancer diagnosis
  • Multiple organ metastases
  • Performance status ECOG ≥3

Goals of Care Considerations:

• Hypercalcemia in metastatic cancer may indicate end-stage disease
• Discuss prognosis and treatment goals with patient/family
• Bisphosphonate treatment may improve quality of life even if not curative
• Consider palliative approach if appropriate

---

Australian/NZ and Indigenous Health Considerations

Australian Clinical Context

Massive Transfusion Protocols:

• Standard in all major trauma centres
• Most use 1:1:1 ratio (PRBCs:FFP:platelets)
• Calcium monitoring/replacement integrated into protocols
• PROPPR trial (PMID: 25647203) evidence informs practice

CRRT Practice:

• Citrate anticoagulation increasingly standard in Australian ICUs
• Prismocitrate (pre-mixed citrate solution) widely used
• Regional citrate anticoagulation extends filter life, reduces bleeding
• Requires careful calcium monitoring

Post-Thyroidectomy Care:

• Day-case or short-stay thyroidectomy becoming more common
• Standardised hypocalcemia monitoring protocols essential
• Most hypocalcemia detected within 24-48 hours
• Early discharge may miss delayed hypocalcemia

PBS Considerations:

• Zoledronic acid (Zometa): PBS-listed for hypercalcemia of malignancy
• Denosumab (Xgeva): PBS-listed for skeletal-related events in malignancy
• Calcitriol: PBS-listed for hypoparathyroidism, CKD

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples (PMID: 25187269):

Vitamin D Deficiency:

• Prevalence 30-50% (higher than general population)
• Contributing factors:
  • Darker skin pigmentation (reduces vitamin D synthesis)
  • Geographic remoteness (limited dietary diversity)
  • Traditional indoor living during hot weather
  • Higher rates of obesity
  • Higher rates of chronic kidney disease

Chronic Kidney Disease:

• 5-10× higher rates of ESKD
• Earlier onset (median age 48 vs 63 years)
• Associated with higher rates of:
  • CKD-MBD (mineral bone disease)
  • Secondary hyperparathyroidism
  • Hypocalcemia

Access Barriers:

• Limited access to specialist endocrine services
• Delayed presentation with hypercalcemia of malignancy
• Geographic isolation from tertiary centres
• Cultural barriers to healthcare engagement

Culturally Safe Care:

• Involve Aboriginal Health Workers (AHW) and Aboriginal Liaison Officers (ALO)
• Family involvement in decision-making essential
• Respect sorry business (bereavement) protocols
• Consider traditional healing integration where appropriate
• Use trained interpreters for language barriers
• Avoid jargon; use visual aids

End-of-Life Considerations:

• Hypercalcemia of malignancy often indicates poor prognosis
• Culturally appropriate discussions about prognosis essential
• "Return to Country" may be priority for terminal patients
• Family conference with appropriate cultural support

Māori Health Considerations (New Zealand):

• Similar vitamin D deficiency patterns
• Higher CKD rates
• Whānau (extended family) involvement essential
• Tikanga (cultural protocols) must be respected
• Māori Health Workers should be involved
• Consider karakia (prayer) and other cultural practices

---

SAQ Practice Questions

SAQ 1: Hypercalcemia of Malignancy

Stem: A 62-year-old male with known metastatic non-small cell lung cancer presents to ICU with confusion and dehydration. He has been increasingly lethargic over the past week with polyuria, nausea, and constipation.

Observations: Temperature 37.2°C, HR 98 bpm, BP 95/60 mmHg, RR 18, SpO2 95% on room air

Laboratory Results:

• Total calcium: 3.8 mmol/L (2.10-2.55)
• Ionized calcium: 1.85 mmol/L (1.10-1.30)
• Phosphate: 0.6 mmol/L (0.8-1.5)
• Albumin: 28 g/L (35-50)
• Creatinine: 185 umol/L (baseline 90)
• PTH: <5 pg/mL (15-65)
• PTHrP: 45 pmol/L (<2.5)

ECG: Sinus tachycardia, shortened QT interval (QTc 320 ms)

Questions (Total 20 marks):

a) Describe the pathophysiology of hypercalcemia in this patient. (4 marks)

b) Outline your initial ICU management priorities for the first 6 hours. (8 marks)

c) The patient's calcium remains elevated at 3.2 mmol/L after 48 hours despite aggressive management. What further options are available? (4 marks)

d) The patient's family asks about prognosis. How would you approach this discussion? (4 marks)

---

Model Answer:

a) Pathophysiology (4 marks):

This patient has humoral hypercalcemia of malignancy (HHM) due to paraneoplastic PTH-related peptide (PTHrP) secretion:

• Elevated PTHrP (45 pmol/L) confirms humoral mechanism (1 mark)
• Suppressed PTH (<5 pg/mL) indicates appropriate negative feedback from hypercalcemia (1 mark)
• PTHrP binds PTH/PTHrP receptor with similar affinity to PTH, causing:
  • Increased bone resorption via osteoclast activation (0.5 mark)
  • Increased renal calcium reabsorption in distal tubule (0.5 mark)
  • Decreased renal phosphate reabsorption (explains hypophosphataemia) (0.5 mark)
• Low phosphate is characteristic of PTHrP-mediated (unlike osteolytic which has normal/high phosphate) (0.5 mark)

b) Initial ICU Management (8 marks):

Immediate priorities (0-6 hours):

1. Volume Resuscitation (FIRST PRIORITY) (2 marks):

   • Normal saline 200-500 mL/hr initially
   • Target urine output 200-300 mL/hr
   • May require 3-6 L in first 24 hours
   • Monitor for volume overload (JVP, lung crackles)
   • Addresses dehydration AND increases renal calcium excretion

2. Monitoring (2 marks):

   • Continuous ECG (shortened QT, arrhythmia risk)
   • Ionized calcium q4-6h
   • Renal function (expect improvement with hydration)
   • Urine output hourly (target 200-300 mL/hr)
   • Electrolytes (K+, Mg2+ may need replacement)

3. Bisphosphonate (2 marks):

   • Zoledronic acid 4 mg IV over 15 minutes
   • Adjust for renal function (consider dose reduction or pamidronate if CrCl <30)
   • Onset 24-72 hours (not immediate)
   • Mechanism: Inhibits osteoclast-mediated bone resorption

4. Calcitonin (bridge therapy) (1 mark):

   • Calcitonin 4 IU/kg SC q12h
   • Rapid onset (4-6 hours)
   • Bridges gap while awaiting bisphosphonate effect
   • Expect tachyphylaxis in 48-72 hours

5. General measures (1 mark):

   • Avoid thiazides, calcium supplements, vitamin D
   • Early mobilisation if possible
   • Avoid nephrotoxins
   • DVT prophylaxis

c) Refractory Hypercalcemia Options (4 marks):

1. Denosumab 120 mg SC (1 mark):

   • RANKL inhibitor; prevents osteoclast maturation
   • Effective when bisphosphonates fail
   • Safe in renal impairment (not renally cleared)
   • Onset 2-4 days

2. Dialysis (1 mark):

   • Haemodialysis with low-calcium dialysate
   • Indicated if severe (>4.5 mmol/L) or renal failure
   • Provides rapid calcium removal
   • Consider CRRT for sustained control

3. Glucocorticoids (0.5 mark):

   • Less effective in PTHrP-mediated hypercalcemia
   • May have role if concurrent haematological malignancy

4. Oncology review (1 mark):

   • Cancer-directed therapy if appropriate
   • Chemotherapy/immunotherapy may reduce PTHrP production
   • Palliative care involvement if treatment options exhausted

5. Repeat bisphosphonate (0.5 mark):

   • Consider alternative bisphosphonate (pamidronate if zoledronic acid used)
   • May repeat zoledronic acid after 7 days if partial response

d) Prognosis Discussion (4 marks):

Approach:

1. Setting and preparation (1 mark):

   • Quiet, private environment
   • Appropriate support (family, cultural liaison if Aboriginal/Torres Strait Islander)
   • Allow adequate time without interruptions

2. Prognostic information (1.5 marks):

   • Hypercalcemia of malignancy indicates advanced disease
   • Median survival 30-90 days without cancer treatment response
   • Better if cancer responds to treatment; worse if refractory
   • Current hypercalcemia may be controlled but will likely recur

3. Goals of care discussion (1 mark):

   • Explore patient's values and priorities
   • Discuss what matters most (comfort, time with family, quality of life)
   • Address realistic treatment options
   • Consider palliative care involvement

4. Supportive communication (0.5 mark):

   • Express empathy and provide emotional support
   • Ensure understanding; invite questions
   • Document discussion and plan
   • Offer follow-up family meetings

---

SAQ 2: Post-Thyroidectomy Hypocalcemia

Stem: A 48-year-old Aboriginal woman presents to the ICU 8 hours after total thyroidectomy for papillary thyroid carcinoma with central lymph node dissection. She reports perioral tingling and numbness in her fingers. The surgical team is concerned about hypocalcemia.

Observations: HR 95 bpm, BP 128/75 mmHg, RR 20, SpO2 98% on room air. Chvostek's sign is positive; Trousseau's sign is equivocal.

Laboratory Results:

• Ionized calcium: 0.92 mmol/L (1.10-1.30)
• Total calcium: 1.85 mmol/L (2.10-2.55)
• PTH: 8 pg/mL (15-65)
• Magnesium: 0.65 mmol/L (0.70-1.00)
• Phosphate: 1.8 mmol/L (0.8-1.5)

ECG: Sinus rhythm, QTc 495 ms

Questions (Total 20 marks):

a) Explain the mechanisms of hypocalcemia in this patient. (4 marks)

b) Describe your immediate management. (8 marks)

c) The patient develops inspiratory stridor 2 hours later. What is your immediate action? (4 marks)

d) Discuss the Indigenous health considerations relevant to this case. (4 marks)

---

Model Answer:

a) Mechanisms of Hypocalcemia (4 marks):

This patient has post-thyroidectomy hypoparathyroidism:

1. Parathyroid gland injury/devascularisation (2 marks):

   • Total thyroidectomy with lymph node dissection puts all four parathyroid glands at risk
   • May be transient (stunning, devascularisation) or permanent (removal, infarction)
   • PTH 8 pg/mL confirms inappropriately low PTH for the calcium level
   • Incidence: 20-30% transient, 1-2% permanent after total thyroidectomy

2. Hypomagnesaemia contributing (1 mark):

   • Mg2+ 0.65 mmol/L is low
   • Magnesium required for PTH secretion AND peripheral PTH action
   • May impair calcium correction if not addressed

3. Elevated phosphate (0.5 mark):

   • PTH normally promotes phosphate excretion
   • Low PTH → phosphate retention
   • High phosphate further complexes ionized calcium

4. Aboriginal patient - possible pre-existing vitamin D deficiency (0.5 mark):

   • Higher prevalence of vitamin D deficiency in Indigenous Australians
   • May exacerbate hypocalcemia if vitamin D insufficient

b) Immediate Management (8 marks):

1. Intravenous Calcium Replacement (3 marks):

   • Calcium gluconate 10% 20 mL (2 ampoules) IV over 10-20 minutes
   • Follow with continuous infusion: 100 mL (10 ampoules) in 1L NS at 50-100 mL/hr
   • Titrate to maintain iCa2+ >1.0 mmol/L
   • Target symptom resolution
   • If central line available and unstable: calcium chloride 10 mL IV

2. Magnesium Replacement (1.5 marks):

   • MgSO4 2 g (8 mmol) IV over 20-60 minutes
   • Essential - hypocalcemia will be refractory without magnesium correction
   • Consider maintenance infusion or regular boluses

3. Monitoring (1.5 marks):

   • Continuous ECG (QTc prolongation, arrhythmia risk)
   • iCa2+ every 2 hours until stable, then q4-6h
   • Magnesium levels q6-12h
   • Watch for signs of tetany, laryngospasm

4. Initiate Oral Replacement (1 mark):

   • Calcium carbonate 1-2 g three times daily
   • Calcitriol 0.5 mcg twice daily (active vitamin D; PTH required to activate cholecalciferol)
   • Transition from IV to oral when stable and tolerating oral intake

5. Surgical Communication (0.5 mark):

   • Inform ENT/surgical team of hypocalcemia
   • Document PTH level (prognostic for permanent vs transient)
   • Plan for ongoing surveillance

6. Airway Monitoring (0.5 mark):

   • High-risk for laryngospasm
   • Have airway equipment readily available
   • Monitor for stridor, voice changes, dyspnoea

c) Stridor Management (4 marks):

This is a medical emergency - hypocalcemic laryngospasm:

1. Call for help (0.5 mark):

   • Emergency response / ICU team
   • ENT surgeon (for potential surgical airway/haematoma)
   • Anaesthetist

2. Immediate Calcium Administration (1.5 marks):

   • Calcium chloride 10 mL of 10% IV push over 2-3 minutes (central line)
   • OR Calcium gluconate 20 mL of 10% IV push over 2-3 minutes (peripheral)
   • Aim for rapid increase in ionized calcium

3. Airway Assessment and Preparation (1.5 marks):

   • High-flow oxygen
   • Prepare for intubation (difficult airway anticipated due to post-surgical oedema)
   • Have surgical airway equipment available
   • Consider nebulised adrenaline 5 mg if laryngeal oedema component
   • Assess for surgical haematoma (may require urgent neck exploration)

4. Exclude/Treat Haematoma (0.5 mark):

   • Expanding neck haematoma can cause airway compromise
   • If suspected: urgent bedside wound opening, surgical exploration

d) Indigenous Health Considerations (4 marks):

1. Pre-existing Vitamin D Deficiency (1 mark):

   • 30-50% prevalence in Aboriginal Australians
   • Darker skin pigmentation reduces vitamin D synthesis
   • Should check 25(OH)D level and replace if deficient
   • May contribute to severity of hypocalcemia

2. Family and Cultural Support (1.5 marks):

   • Involve Aboriginal Health Worker (AHW) and Aboriginal Liaison Officer (ALO)
   • Extended family involvement in care decisions is culturally important
   • Ensure culturally safe environment
   • Use trained interpreter if needed
   • Explain condition and treatment in accessible language

3. Healthcare Access and Follow-up (1 mark):

   • Assess ability to attend follow-up (remote community, transport)
   • Arrange telehealth or local clinic follow-up if remote
   • Ensure adequate supply of oral calcium and calcitriol
   • Provide clear written and verbal instructions
   • Consider extended hospital stay if follow-up uncertain

4. Holistic Care (0.5 mark):

   • Address any anxiety or fear about diagnosis (cancer)
   • Offer social work/emotional support
   • Consider integration of traditional healing if desired by patient
   • Ensure continuity with primary care provider

---

Viva Scenarios

Viva 1: Calcium Homeostasis and Hypocalcemia (with ECG Interpretation)

Examiner: You are the intensive care registrar. A 45-year-old man has been admitted post-massive transfusion following a motor vehicle accident. He received 12 units of PRBCs and 8 units of FFP over 4 hours. He is now haemodynamically unstable on noradrenaline 0.3 mcg/kg/min. This is his ECG. [Shows ECG with prolonged QT interval, QTc 520 ms]

---

Examiner: Describe the relevant features of this ECG.

Candidate: This ECG shows sinus rhythm at approximately 85 bpm. The key abnormality is a markedly prolonged QT interval. The QTc is approximately 520 ms, which is significantly prolonged above the normal limit of 450 ms in males.

Looking specifically at the morphology, the prolongation appears to be predominantly in the ST segment rather than the T wave itself. This pattern is characteristic of hypocalcemia, as opposed to hypokalaemia where we would expect prominent U waves and T wave flattening.

Other features I would look for include T wave changes, any evidence of ischaemia, and comparison with previous ECGs if available.

Examiner: Good. What are the risks associated with this QT prolongation?

Candidate: The main risk is Torsades de Pointes, a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation. The risk is particularly high when QTc exceeds 500 ms, which this patient has.

Risk factors that increase the likelihood of Torsades in this patient include:

• Severe hypocalcemia
• Possibly concurrent hypomagnesaemia and hypokalaemia
• Catecholamine infusion (may trigger early afterdepolarizations)
• Female sex would increase risk (but this is a male patient)

Examiner: What do you think is causing the hypocalcemia in this patient?

Candidate: This patient has received massive transfusion, which is the most likely cause of his hypocalcemia. Blood products contain citrate as an anticoagulant. Each unit of PRBCs contains approximately 3 grams of citrate, and FFP contains even more - around 5 grams per unit.

Citrate chelates ionized calcium, forming inactive calcium-citrate complexes. Normally, the liver metabolises citrate rapidly, but with rapid transfusion rates exceeding 1 unit per 5 minutes, hepatic metabolism is overwhelmed.

This patient has received 12 units PRBCs and 8 units FFP over 4 hours - that's approximately 76 grams of citrate. His liver cannot keep up with this load.

Additional factors that impair citrate metabolism and worsen hypocalcemia include:

• Hypothermia (common in massive transfusion)
• Hypoperfusion and shock (reduced hepatic blood flow)
• Pre-existing liver dysfunction
• Acidosis

This has been described as the "lethal diamond"

• extending the classic lethal triad of hypothermia, acidosis, and coagulopathy to include hypocalcemia as the fourth factor.

Examiner: How would you confirm and quantify the hypocalcemia?

Candidate: I would measure ionized calcium directly using a blood gas analyser. This is the gold standard in ICU patients and the physiologically active fraction.

Total calcium corrected for albumin is unreliable in critical illness because:

• Albumin correction formulas assume normal pH and protein binding
• Acid-base disturbances alter protein binding
• Citrate itself complexes calcium
• Concordance with ionized calcium is less than 50% in ICU patients

In massive transfusion, I would expect iCa2+ to be significantly reduced - likely less than 1.0 mmol/L given the ECG changes and haemodynamic instability.

Examiner: His ionized calcium is 0.72 mmol/L. How would you manage this?

Candidate: This is severe hypocalcemia requiring urgent treatment. My approach would be:

Immediate Actions:

1. Calcium Chloride 10% - 10 mL IV via central line over 2-3 minutes

   • I would use calcium chloride rather than gluconate because he has central access, is haemodynamically unstable, and calcium chloride provides 3 times more elemental calcium per mL
   • This will provide a rapid increase in ionized calcium

2. Recheck ionized calcium in 5-10 minutes

   • May need to repeat bolus if inadequate response

3. Start calcium infusion - 10 ampoules of 10% calcium gluconate in 1L of normal saline, running at 50-100 mL/hr

   • Titrate to maintain iCa2+ above 1.0 mmol/L

4. Ongoing monitoring:

   • iCa2+ every 30-60 minutes during active transfusion
   • Continuous ECG for QT normalisation and arrhythmia detection
   • Monitor for signs of calcium toxicity (bradycardia, hypotension from rapid bolus)

5. Address contributing factors:

   • Active rewarming to improve hepatic citrate metabolism
   • Check and correct magnesium (often low concurrently)
   • Slow transfusion rate if clinically possible

Examiner: Can you explain the physiology of how calcium affects cardiac contractility and why hypocalcemia causes haemodynamic instability?

Candidate: Calcium is essential for cardiac excitation-contraction coupling.

During the cardiac action potential, calcium enters the myocyte through L-type voltage-gated calcium channels during phase 2 (the plateau phase). This "trigger calcium" binds to ryanodine receptors on the sarcoplasmic reticulum, causing release of stored calcium - this is calcium-induced calcium release.

The released calcium binds to troponin C on the thin filaments, causing a conformational change that allows actin-myosin cross-bridge formation and contraction.

In hypocalcemia:

• Less calcium enters through L-type channels
• Smaller calcium-induced calcium release
• Reduced troponin C activation
• Weaker myocardial contraction
• Reduced cardiac output

Additionally, hypocalcemia impairs vascular smooth muscle contraction, contributing to vasodilation and hypotension.

Importantly, hypocalcemia also reduces the response to catecholamines and inotropes. This patient is on noradrenaline and may have a blunted response until his calcium is corrected. This is a critical concept in massive transfusion - without adequate calcium, vasopressors and inotropes will be less effective.

Examiner: What about magnesium - why is it important to check and correct this?

Candidate: Magnesium is critically important in calcium homeostasis for two reasons:

1. PTH secretion requires magnesium - Severe hypomagnesaemia inhibits PTH release from the parathyroid glands. Without PTH, the body cannot mobilise calcium from bone or increase renal calcium reabsorption.

2. PTH action requires magnesium - Even if PTH is released, target organs (bone and kidney) are resistant to its effects in the setting of hypomagnesaemia.

This means that hypocalcemia will be refractory to calcium replacement unless magnesium is also corrected.

Hypomagnesaemia is common in massive transfusion because:

• Citrate also chelates magnesium
• Losses during surgery
• Dilution with crystalloid resuscitation

I would check magnesium and if low, give 2 grams of magnesium sulfate IV over 20-60 minutes, followed by maintenance replacement.

---

Viva 2: Hypercalcemia and ECG Interpretation

Examiner: A 58-year-old woman with known breast cancer and bone metastases presents to ICU with confusion and lethargy. Her ionized calcium is 1.95 mmol/L. This is her ECG. [Shows ECG with shortened QT interval, QTc 310 ms, and subtle J waves]

---

Examiner: Please interpret this ECG.

Candidate: This ECG shows sinus rhythm at approximately 70 bpm. The striking abnormality is a markedly shortened QT interval. The QTc is approximately 310 ms, which is well below the normal limit of 350 ms.

Looking at the morphology, the shortening appears to be predominantly in the ST segment, which is almost absent - the T wave follows almost immediately after the QRS complex. This is the classic appearance of hypercalcemia.

I can also see subtle J waves - small positive deflections at the J point junction between QRS and ST segment. These Osborn waves are classically associated with hypothermia but can also be seen in severe hypercalcemia.

There's no evidence of significant bradycardia, heart block, or other arrhythmias at present, but these can occur with severe hypercalcemia.

Examiner: Explain the mechanism of the shortened QT in hypercalcemia.

Candidate: The QT interval represents ventricular depolarisation and repolarisation. The ST segment corresponds to the plateau phase (phase 2) of the cardiac action potential.

During the plateau phase, calcium influx through L-type calcium channels balances potassium efflux, maintaining the membrane potential.

In hypercalcemia:

• The increased extracellular calcium concentration creates a larger electrochemical gradient
• This accelerates calcium influx during phase 2
• More rapid calcium entry leads to faster inactivation of L-type calcium channels
• The plateau phase is shortened
• This accelerates repolarisation
• Result: Shortened ST segment and QT interval

Additionally, hypercalcemia increases the threshold for action potential generation, which can lead to decreased excitability and conduction delays - explaining the PR prolongation and bradycardia seen in severe cases.

Examiner: What is the mechanism of hypercalcemia in this patient?

Candidate: This patient has breast cancer with bone metastases. There are two mechanisms that may be contributing:

1. Local Osteolytic Hypercalcemia (LOH):

   • Direct bone destruction by metastatic tumour cells
   • Tumour cells secrete cytokines (IL-1, IL-6, TNF-α) and RANKL
   • These activate osteoclasts to resorb bone
   • Releases calcium from the bone matrix
   • Accounts for approximately 20% of hypercalcemia of malignancy

2. Humoral Hypercalcemia of Malignancy (HHM):

   • Breast cancer can also secrete PTH-related peptide (PTHrP)
   • PTHrP binds to the same receptor as PTH
   • Causes increased bone resorption and renal calcium reabsorption
   • More common mechanism overall (80% of malignancy-associated hypercalcemia)

To distinguish these, I would check:

• PTH - should be suppressed in both (appropriate response to hypercalcemia)
• PTHrP - elevated in HHM, normal in LOH
• Phosphate - low in HHM (PTHrP causes phosphaturia), normal/high in LOH

Many patients with bone metastases have components of both mechanisms.

Examiner: Her PTH is suppressed at 3 pg/mL and PTHrP is 55 pmol/L (elevated). How would you manage this patient?

Candidate: This confirms humoral hypercalcemia of malignancy. My management approach:

Phase 1: Volume Resuscitation (First Priority)

• Normal saline 200-500 mL/hr initially
• Target urine output 200-300 mL/hr
• These patients are typically volume-depleted (hypercalcemia causes polyuria)
• Volume expansion improves GFR and increases urinary calcium excretion
• May require 3-6 litres in first 24 hours
• Monitor for volume overload

Phase 2: Inhibit Bone Resorption

Bisphosphonate:

• Zoledronic acid 4 mg IV over 15 minutes
• This is the first-line bone-active agent
• Mechanism: Binds hydroxyapatite, inhibits osteoclast function, induces osteoclast apoptosis
• Onset: 24-72 hours
• Duration: 2-4 weeks
• Adjust for renal function

Calcitonin (bridge therapy):

• Calcitonin 4-8 IU/kg SC q12h
• Rapid onset (4-6 hours)
• Bridges the gap while awaiting bisphosphonate effect
• Tachyphylaxis develops in 48-72 hours due to receptor downregulation
• Can discontinue once bisphosphonate working

Phase 3: Other Measures

• Loop diuretics only after volume replete (may worsen dehydration if given too early)
• Avoid thiazides, calcium supplements, vitamin D
• Mobilise patient if possible
• Discontinue lithium if applicable

Phase 4: Cancer-Directed Therapy

• Oncology consultation for treatment of underlying breast cancer
• Chemotherapy/endocrine therapy may reduce PTHrP production

Examiner: After 48 hours of treatment, her calcium has only improved to 1.65 mmol/L. What would you do next?

Candidate: This is bisphosphonate-refractory hypercalcemia. Options include:

1. Denosumab 60-120 mg SC:

   • RANKL inhibitor - prevents osteoclast maturation and function
   • Different mechanism to bisphosphonates
   • Onset 2-4 days
   • Major advantage: Safe in renal impairment (not renally cleared)
   • Important: Warn about rebound hypercalcemia when discontinued

2. Repeat or alternative bisphosphonate:

   • Consider pamidronate if zoledronic acid used initially
   • Can repeat zoledronic acid after 7 days if partial response

3. Dialysis:

   • If calcium remains severely elevated (>4.0 mmol/L)
   • If renal function is impaired
   • Use low-calcium or calcium-free dialysate
   • CRRT for sustained calcium control

4. Glucocorticoids:

   • Less effective in PTHrP-mediated hypercalcemia
   • May have role if concurrent lymphoma or myeloma

5. Reassess goals of care:

   • Hypercalcemia of malignancy indicates advanced disease
   • Median survival 30-90 days without response to cancer treatment
   • Discuss prognosis and priorities with patient and family
   • Palliative care involvement may be appropriate

Examiner: The family are distressed and asking about prognosis. How would you approach this conversation?

Candidate: This is a difficult but essential conversation. My approach:

Preparation:

• Ensure private, quiet environment
• Have appropriate team members present
• Allow adequate time
• Review what family already knows

The Conversation:

1. Assess understanding: "Can you tell me what you understand about your mother's condition?"

2. Provide clear information:

   • Explain that hypercalcemia in the setting of metastatic cancer often indicates the disease is advancing
   • The high PTHrP level means the cancer is very active
   • Despite our best treatment, this type of hypercalcemia often recurs

3. Give prognostic information sensitively:

   • "When calcium rises like this with advanced cancer, it usually means the outlook is measured in weeks to months rather than longer"
   • Acknowledge uncertainty while being honest about the seriousness

4. Explore goals and values:

   • What matters most to the patient?
   • What would she want if her condition worsens?
   • Has she expressed any wishes about end-of-life care?

5. Discuss options:

   • We can continue to treat the calcium to maintain comfort and quality of life
   • Oncology will advise on whether further cancer treatment is appropriate
   • Palliative care can help with symptom management

6. Provide support:

   • Acknowledge the distress
   • Offer pastoral care, social work support
   • Ensure they can contact us with questions
   • Plan follow-up meetings

For Indigenous patients, I would involve Aboriginal Health Workers and Liaison Officers, ensure extended family involvement, and respect cultural protocols around serious illness and end-of-life discussions.

---

Zoledronic acid: 24-72 hours; Calcitonin: 4-6 hours (hence calcitonin as bridge)

46. Q: What is the NICE-SUGAR study relevance to calcium? A: NICE-SUGAR (PMID: 19318384): Intensive glucose control study; highlighted electrolyte monitoring importance including calcium in critical illness

47. Q: What is the evidence base for calcium gluconate vs chloride efficacy? A: Calcium chloride provides more rapid increase in ionized calcium; preferred in cardiac arrest (ARC/ANZCOR guidelines)

48. Q: What is the prevalence of vitamin D deficiency in Aboriginal Australians? A: 30-50%, higher than general population (PMID: 25187269)

49. Q: What is the citrate load per unit of FFP? A: Approximately 5 grams (more than PRBCs which contain ~3g)

50. Q: What is the recommended monitoring frequency for iCa2+ during citrate-CRRT? A: Every 4-6 hours initially, then every 12 hours when stable; systemic and post-filter iCa2+ monitored separately

---

References

Key Guidelines and Statements

1. Endocrine Society. Clinical Practice Guideline on Vitamin D Deficiency. 2011. PMID: 21646368
2. KDIGO CKD-MBD Guidelines 2017. PMID: 30675420
3. ANZICS-CORE Massive Transfusion Protocol Statement. 2011.
4. Therapeutic Guidelines Australia - Endocrinology. 2024.

Landmark Studies

5. Zaloga GP, Chernow B. The multifactorial basis for hypocalcemia during sepsis. Ann Intern Med. 1987;107(1):36-41. PMID: 3592446
6. Zivin JR, Gooley T, Zager RA, Ryan MJ. Hypocalcemia: a pervasive metabolic abnormality in the critically ill. Am J Kidney Dis. 2001;37(4):689-698. PMID: 11273867
7. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. PMID: 21646368
8. Egi M, Kim I, Nichol A, et al. Ionized calcium concentration and outcome in critical illness. Crit Care Med. 2011;39(2):314-321. PMID: 21099426
9. Steele T, Kolamunnage-Dona R, Downey C, et al. Assessment and clinical course of hypocalcemia in critical illness. Crit Care. 2013;17(3):R106. PMID: 23734769

Calcium Physiology and Homeostasis

10. Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab. 2007;3(2):122-133. PMID: 17237839
11. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81(1):239-297. PMID: 11152759
12. Felsenfeld AJ, Levine BS. Calcitonin, the forgotten hormone: does it deserve to be forgotten? Clin Kidney J. 2015;8(2):180-187. PMID: 25815174
13. Bouillon R, Marcocci C, Carmeliet G, et al. Skeletal and extraskeletal actions of vitamin D: Current evidence and outstanding questions. Endocr Rev. 2019;40(4):1109-1151. PMID: 30321335

Hypocalcemia

14. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391-403. PMID: 18650515
15. Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ. 2008;336(7656):1298-1302. PMID: 18535072
16. Rude RK, Singer FR, Gruber HE. Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr. 2009;28(2):131-141. PMID: 19828898
17. Agus ZS. Hypomagnesemia. J Am Soc Nephrol. 1999;10(7):1616-1622. PMID: 10405219
18. Fatemi S, Ryzen E, Flores J, et al. Effect of experimental human magnesium depletion on parathyroid hormone secretion and 1,25-dihydroxyvitamin D metabolism. J Clin Endocrinol Metab. 1991;73(5):1067-1072. PMID: 8621774

Hypercalcemia

19. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373-379. PMID: 15673803
20. Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7(10):1722-1729. PMID: 22879438
21. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-567. PMID: 11208851
22. Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014;99(9):3144-3152. PMID: 24915117
23. Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag. 2015;11:1779-1788. PMID: 26675714

ECG and Cardiac Effects

24. El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J. 2011;18(3):233-245. PMID: 21660912
25. Slovis C, Jenkins R. ABC of clinical electrocardiography: Conditions not primarily affecting the heart. BMJ. 2002;324(7349):1320-1323. PMID: 12039833
26. Surawicz B. Relationship between electrocardiogram and electrolytes. Am Heart J. 1967;73(6):814-834. PMID: 5338053

Massive Transfusion and Critical Care

27. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482. PMID: 25647203
28. Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev. 1988;2(2):76-94. PMID: 3154656
29. Maxwell MJ, Wilson MJA. Complications of blood transfusion. Contin Educ Anaesth Crit Care Pain. 2006;6(6):225-229.
30. Vivien B, Langeron O, Riou B. Increase in ionized calcium during massive transfusion in trauma patients. Crit Care Med. 2005;33(7):1607-1608. PMID: 16003072

CRRT and Citrate Anticoagulation

31. Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy - heparin or citrate? Crit Care. 2011;15(1):202. PMID: 21345279
32. Tolwani A, Wille KM. Advances in continuous renal replacement therapy: citrate anticoagulation update. Blood Purif. 2012;34(2):88-93. PMID: 23095405
33. Oudemans-van Straaten HM, Ostermann M. Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice. Crit Care. 2012;16(6):249. PMID: 23216866
34. Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol. 2014;9(12):2173-2188. PMID: 24855160

Post-Thyroidectomy

35. Bergenfelz A, Jansson S, Kristoffersson A, et al. Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbecks Arch Surg. 2008;393(5):667-673. PMID: 18633639
36. Roh JL, Park CI. Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy. Am J Surg. 2006;192(5):675-678. PMID: 17071205
37. Eismontas V, Slepavicius A, Janusonis V, et al. Predictors of postoperative hypocalcemia occurring after a total thyroidectomy: results of prospective multicenter study. BMC Surg. 2018;18(1):55. PMID: 30119666

Australian/Indigenous Health

38. Daly RM, Gagnon C, Lu ZX, et al. Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clin Endocrinol (Oxf). 2012;77(1):26-35. PMID: 22168576
39. Nowson CA, McGrath JJ, Ebeling PR, et al. Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust. 2012;196(11):686-687. PMID: 22708765
40. Maple-Brown L, Cunningham J, Dunne K, et al. Complications of diabetes in urban Indigenous Australians: the DRUID study. Diabetes Res Clin Pract. 2008;80(3):455-462. PMID: 18325624
41. AIHW. Aboriginal and Torres Strait Islander Health Performance Framework 2017 Report. 2017.

Ionized vs Total Calcium

42. Byrnes MC, Huynh K, Helmer SD, et al. A comparison of corrected serum calcium levels to ionized calcium levels among critically ill surgical patients. Am J Surg. 2005;189(3):310-314. PMID: 15792757
43. Ladenson JH, Lewis JW, Boyd JC. Failure of total calcium corrected for protein, albumin, and pH to correctly assess free calcium status. J Clin Endocrinol Metab. 1978;46(6):986-993. PMID: 45478
44. Slomp J, van der Voort PH, Gerritsen RT, et al. Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill. Crit Care Med. 2003;31(5):1389-1393. PMID: 12771608

Calcitonin and Bisphosphonates

45. Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int. 1990;46 Suppl:S26-30. PMID: 2194232
46. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-567. PMID: 11208851
47. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med. 1981;50(200):473-481. PMID: 7342172
48. Ralston SH, Gallacher SJ, Patel U, et al. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990;112(7):499-504. PMID: 2107781

---

Related Topics

Prerequisites:

• Electrolyte Disorders
• Renal Physiology
• Massive Transfusion

Consequences/Complications:

• Cardiac Arrhythmias
• Renal Replacement Therapy
• Acute Kidney Injury

Related Conditions:

• Hypomagnesemia
• Thyroid Emergencies
• CKD in ICU
• Malignancy in ICU